Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor

Masaru Hirano,Dan Meyers,GangaRaju Golla,Parasar Pal,Pascale Pinot,TsuHan Lin,Tapan Majumdar,Sam Rebello,Gangadhar Sunkara,Jin Chen

Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor

2015

Masaru Hirano
Dan Meyers
GangaRaju Golla
Parasar Pal
Pascale Pinot
TsuHan Lin
Tapan Majumdar
Sam Rebello
Gangadhar Sunkara
Jin Chen

Background and Objective Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, is under development to treat familial chylomicronemia syndrome. The potential impact of hepatic impairment on the pharmacokinetics of pradigastat was evaluated in this study.

Keywords:

Hepatic impairment
Pradigastat
Familial Chylomicronemia
Pharmacology
Pharmacokinetics
Diabetes mellitus
Medicine
Diacylglycerol Acyltransferase
Endocrinology
Internal medicine
Diacylglycerol kinase
clinical study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations